Monday, May 20, 2013
At first blush, new Shire plc
CEO Flemming Ornskov's plan to invest in early R&D while integrating
business units looks like a rehash of the company's strategy from 2000. But
Ornskov expects the latest move will actually help align resources and
potentially broaden the company's specialty pipeline.
Until 2000, Shire was a growth
through acquisition company with little internal R&D. That all changed in
2000, with the acquisition of BioChem Pharma Inc. and the company's decision to
focus more on R&D (see BioCentury, Dec. 18, 2000).